🇺🇸 FDA
Patent

US 10982215

Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

granted A61KA61K31/7088A61K31/712

Quick answer

US patent 10982215 (Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/7088, A61K31/712, A61K31/7125, A61K45/06